<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350609</url>
  </required_header>
  <id_info>
    <org_study_id>14028</org_study_id>
    <secondary_id>2011-000322-29</secondary_id>
    <nct_id>NCT01350609</nct_id>
  </id_info>
  <brief_title>Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed</brief_title>
  <official_title>Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan and the Loose Combination of Both Components and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Subjects Under Fed Conditions in an Open Label, Randomized, 2-way-crossover Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, open label, single dose, 2-way crossover study to investigate the bioequivalence
      of a new fixed dose combination (FDC) tablet of nifedipine GITS and candesartan with the
      corresponding loose combination under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical pharmacology
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>within 48 hours after each dosing</time_frame>
    <description>Maximum drug concentration in plasma after dose administration for nifedipine and candesartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)</measure>
    <time_frame>within 48 hours after each dosing</time_frame>
    <description>Area under the drug-concentration vs. time curve from time 0 to the last data point for nifedipine and candesartan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Within 48 hours after each dosing</time_frame>
    <description>Area under the curve from time 0 to infinity after single dose for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,norm</measure>
    <time_frame>Within 48 hours after each dosing</time_frame>
    <description>Dose normalized Cmax for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCnorm</measure>
    <time_frame>Within 48 hours after each dosing</time_frame>
    <description>AUC normalized for dose and body weight for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-48)</measure>
    <time_frame>Within 48 hours after each dosing</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to 48h for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Within 48 hours after each dosing</time_frame>
    <description>The time of the maximum concentration for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Within 48 hours after each dosing</time_frame>
    <description>Half-life for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT</measure>
    <time_frame>Within 48 hours after each dosing</time_frame>
    <description>The mean residence time for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Within 48 hours after each dosing</time_frame>
    <description>Oral plasma clearances for nifedipine and candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 3-7 weeks per subject</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hypertension, Essential</condition>
  <arm_group>
    <arm_group_label>Nifedipine/Candesartan (fixed dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine/Candesartan (loose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine/Candesartan (BAY 98-7106)</intervention_name>
    <description>Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)</description>
    <arm_group_label>Nifedipine/Candesartan (fixed dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)</intervention_name>
    <description>Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .</description>
    <arm_group_label>Nifedipine/Candesartan (loose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The informed consent form must be signed before any study specific tests or procedures
             are done

          -  Confirmation of the subject's health insurance coverage prior to the first screening
             visit

          -  Healthy male subject

          -  Ethnicity: Caucasian

          -  Age: 18 to 45 years (inclusive) at the first screening visit

          -  Body mass index (BMI) above or equal 18, and below or equal 29.9 kg / mÂ²

          -  Ability to understand and follow study-related instructions

        Exclusion Criteria:

          -  Suspicion of drug or alcohol abuse

          -  Regular daily consumption of more than 1 L of xanthin-containing beverages

          -  Intake of foods or beverages containing grapefruit within 2 weeks prior to the first
             study drug administration (the same applies to pomelos and St. John's Wort)

          -  Use of medication within 4 weeks prior to the first study drug administration which
             could interfere with the investigational products (e.g. CYP3A inhibitors or CYP3A
             inducers)

               -  examples for CYP3A inhibitors: erythromycin, inhibitors of human HIV protease
                  (e.g. ritonavir, saquinavir), amiodarone, diltiazem, verapamil, fluconazole,
                  itraconazole, ketoconazole, clarithromycin, telithromycin, nefazodon, cimetidine;

               -  examples for CYP3A inducers: rifampicin, carbamazepin, phenytoin, phenobarbital,
                  or products containing St. John's Wort;

          -  Systolic blood pressure below 116 or above 145 mmHg (after at least 15 min supine)

          -  At the first screening visit

               -  Diastolic blood pressure above 95 mmHg (after at least 15 min supine)

               -  Heart rate below 45 or above 95 beats / min (after at least 15 min supine) at the
                  first screening visit

               -  Clinically relevant findings in the physical examination

               -  Positive urine drug screening or alcohol breath test

          -  Exclusion periods from other studies or simultaneous participation in other clinical
             studies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>essential hypertension, blood pressure, nifedipine, candesartan, FDC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

